Swiss startup Moonlight AI, a developer of AI-powered diagnostic software, has closed a $3.3 million seed funding round. The investment was co-led by an international group including Lotus One Investment, VP Venture Partners, and MEDIN Fund. This capital will accelerate the company's mission to democratize access to genomic information for faster, more accurate cancer diagnostics.
Revolutionizing Cancer Diagnostics
Precision oncology relies on Next-Generation Sequencing (NGS) for vital genomic data. However, this method presents significant bottlenecks for labs due to its high costs and lengthy turnaround times. These limitations often delay critical diagnoses and restrict patient access to personalized cancer care, creating a need for more efficient alternatives.
Moonlight AI addresses this challenge using advanced computer vision to analyze routine medical images. The company's software detects genomic biomarkers and disease signatures directly from standard blood and cytology smears. This innovative approach bypasses the need for NGS in many cases, converting available images into actionable clinical insights.
According to CEO Christian Ruiz, the technology integrates into existing lab workflows without requiring expensive new hardware. This empowers labs to generate immediate results from slides they already process. Ultimately, this helps scale diagnostic capacity, reduce manual processes, and deliver faster, more precise results to patients.
Strategic Allocation of New Capital
A primary objective for the funding is expanding Moonlight AI's proprietary data library. This unique dataset is the first to connect whole slide imaging of cytopathology samples with high-quality genomic data. Building this resource is fundamental to training and validating the company's diagnostic algorithms for widespread clinical reliability.
CTO Nicole H. Romano emphasized the importance of collaboration in building this resource. By working with an international consortium of clinical partners, the company is curating a diverse dataset. This approach is designed to ensure the AI models are robust and perform accurately across various real-world laboratory settings.
The investment will also expand the company's team and advance its diagnostic solutions. Key focus areas include myelodysplastic syndrome, non-small cell lung cancer, and chronic lymphocytic leukemia. The capital will also accelerate the company's journey toward commercialization and securing essential regulatory approvals for its products.
Investor Confidence and Corporate Growth
The funding round attracted a diverse syndicate of investors from Europe, North Africa, and Asia, signaling strong global confidence. Participants included co-leads Lotus One Investment, VP Venture Partners, and MEDIN Fund, alongside N&V Capital and existing investor QAI Ventures. This broad support underscores the technology's value in the global healthcare market.
Investors expressed strong conviction in the company's mission and leadership. Asmita Dwivedi of Lotus One Investment highlighted the founders' deep clinical and scientific expertise. Other investors noted that Moonlight AI is addressing a critical bottleneck in diagnostics with the potential to significantly improve patient care and lab efficiency.
In a strategic move, Moonlight AI has transitioned into a Swiss Stock Corporation. This corporate restructuring is a key step in preparing the company for its planned international expansion. It also lays the groundwork for the commercial rollout of its AI-driven diagnostic software on a global scale.
This $3.3 million seed funding is a pivotal milestone for Moonlight AI, equipping it with resources to refine its technology and expand its reach. By transforming routine medical images into powerful diagnostic tools, the company is poised to make a significant impact on precision oncology. As it moves toward commercialization, Moonlight AI continues to invite collaboration to shape the future of diagnostics.